Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial

Diabetes Technology&Therapeutics, Ahead of Print.

Source: Diabetes Technology - March 30, 2020 Category: Endocrinology Authors: Satish K. Garg Karin Wernicke-Panten Marek Wardecki Daniel Kramer Francois Delalande Edward Franek Karita Sadeharju Travis Monchamp Patrick Miossec Bhaswati Mukherjee Viral N. Shah Source Type: research